Table 1 PCE exposure history of breast cancer cases and controls
| Â | PCE-exposed cases | PCE-exposed controls | ||
|---|---|---|---|---|
Latency period (years) | Prior analysis (n = 930) | Current analysis (n = 920) | Prior analysis (n = 1302) | Current Analysis (n = 1293) |
0 | 191 (20.5%) | 449 (48.8%) | 217 (16.7%) | 648 (50.1%) |
5 | 154 (16.6%) | 399 (43.4%) | 163 (12.5%) | 552 (42.7%) |
7 | 128 (13.8%) | 365 (39.7%) | 135 (10.4%) | 496 (38.4%) |
9 | 111 (11.9%) | 319 (34.7%) | 110 (8.4%) | 436 (33.7%) |
11 | 86 (9.2%) | 281 (30.5%) | 83 (6.4%) | 376 (29.1%) |
13 | 65 (7.0%) | 242 (26.3%) | 52 (4.0%) | 325 (25.1%) |
15 | 44 (4.7%) | 186 (20.2%) | 35 (2.7%) | 229 (17.7%) |
17 | 21 (2.3%) | 130 (14.1%) | 21 (1.6%) | 141 (10.9%) |
19 | 9 (1.0%) | 84 (9.1%) | 9 (0.7%) | 78 (6.0%) |